Tempus AI (NASDAQ:TEM) Shares Up 2.7% – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM) shares were up 2.7% on Thursday . The company traded as high as $50.25 and last traded at $51.84. Approximately 5,146,128 shares traded hands during mid-day trading, a decline of 33% from the average daily volume of 7,670,926 shares. The stock had previously closed at $50.45.

Analyst Upgrades and Downgrades

A number of research firms have commented on TEM. Bank of America lifted their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Wolfe Research started coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Guggenheim initiated coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.36.

Tempus AI Trading Down 6.3 %

The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The firm has a fifty day moving average price of $44.36 and a 200-day moving average price of $47.59.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, major shareholder Bradley A. Keywell sold 265,000 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the completion of the transaction, the insider now owns 15,218,365 shares of the company’s stock, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric P. Lefkofsky sold 85,788 shares of the stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the completion of the transaction, the chief executive officer now directly owns 5,771,787 shares of the company’s stock, valued at $308,155,707.93. This trade represents a 1.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862,758 shares of company stock valued at $79,585,675 in the last ninety days.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors have recently added to or reduced their stakes in TEM. First Horizon Advisors Inc. acquired a new stake in Tempus AI in the third quarter valued at approximately $30,000. FNY Investment Advisers LLC acquired a new stake in shares of Tempus AI during the 4th quarter valued at $67,000. Vestor Capital LLC bought a new stake in Tempus AI during the 3rd quarter worth $153,000. Stifel Financial Corp acquired a new position in Tempus AI in the 3rd quarter worth about $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in Tempus AI in the third quarter valued at about $258,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.